Hypothesis

Age‑related accumulation of specific somatic copy number variations (CNVs) in hematopoietic stem cells functions as an evolutionarily conserved timer that activates inflammatory senescence pathways, thereby imposing a species‑specific limit on individual lifespan beyond the reproductive window. This mechanism provides a group‑level benefit by reducing resource competition for kin, aligning with the view that aging is a selected feature rather than unselected damage.

Mechanistic Basis

Clonal hematopoiesis (CH) and broader mosaic chromosomal alterations increase with age and are modulated by germline DNA‑repair capacity (3, 4). We propose that certain recurrent CNVs—such as trisomy 8 or loss of the Y chromosome—alter the dosage of genes that regulate the NF‑κB inflammasome and senescence‑associated secretory phenotype (SASP). Increased copy number of pro‑inflammatory cytokines (e.g., IL6, IL1B) or decreased copy number of negative regulators (e.g., A20/TNFAIP3) shifts the balance toward chronic low‑grade inflammation (inflammaging). This inflammatory state impairs tissue repair, promotes fibrosis, and elevates mortality risk independently of traditional cardiovascular or oncogenic drivers.

Because the CNV burden rises predictably with stem‑cell divisions, its kinetics resemble a biological clock. Evolution could have retained this process because the resulting inflammaging reduces individual survival after peak reproductive output, thereby freeing nutrients and space for younger, related individuals—a form of kin selection.

Testable Predictions

1. Individuals with a higher burden of specific age‑associated CNVs (e.g., >5% VAF for trisomy 8 in peripheral blood) will exhibit elevated circulating inflammaging markers (IL‑6, CRP, GDF‑15) at a younger chronological age than matched low‑burden peers, independent of traditional risk factors.
2. Longitudinally, the rate of CNV accumulation will predict time to onset of age‑related multimorbidity (cardiovascular disease, frailty, cancer) better than epigenetic clocks alone.
3. Experimental reduction of the dosage of a key inflammasome‑activating gene (using CRISPR‑based allele‑specific knock‑down in human hematopoietic stem cells) will attenuate SASP secretion in vitro and delay the emergence of inflammatory phenotypes in xenografted mice.
4. In mammalian models where germline DNA‑repair pathways are sensitized to increase somatic CNV rates, lifespan will be shortened proportionally to the increase in CNV burden, and this effect will be rescued by anti‑inflammatory interventions (e.g., NLRP3 inhibitors).

Experimental Approach

• Cohort analysis: Use deep whole‑genome sequencing of longitudinal blood samples from existing aging cohorts (e.g., UK Biobank, Framingham) to quantify clonal CNV VAFs and correlate with serial inflammatory biomarker measures and health‑outcome timing. Apply Cox‑proportional hazards models adjusting for age, sex, smoking, and genetic risk scores.
• In vitro validation: Engineer human induced pluripotent stem cell‑derived hematopoietic lineages to carry defined CNVs via CRISPR‑mediated chromosome engineering. Measure NF‑κB activation, SASP cytokine release, and senescence markers (p16, SA‑β‑gal).
• In vivo validation: Transplant edited hematopoietic stem cells into immunodeficient mice; monitor systemic inflammation, frailty index, and survival. Treat subsets with NLRP3 inhibitor MCC950 to test rescue.
• Cross‑species comparison: Assess whether short‑lived rodent species show accelerated CNV acquisition in hematopoietic compartments relative to longer‑lived species, supporting a conserved clock function.

If the data show that specific somatic CNVs drive inflammaging and that modulating their dosage alters inflammatory output and lifespan, the hypothesis would be supported. Conversely, a lack of correlation between CNV burden and inflammatory markers, or failure of CNV dosage manipulation to affect SASP, would falsify the claim that somatic CNVs constitute a programmed aging mechanism.